OJEpi> Vol.4 No.3, August 2014

Prevalence and Genotype Distribution of Oncogenic-Risk Human Papilloma Virus in the Cervix of Climacteric Women with Normal Pap Smears

DownloadDownload as PDF (Size:2540KB)  HTML    PP. 164-168  

ABSTRACT

Objective: To find out the incidence of high-risk HPV infections on climacteric women within our area of influence; and to typify HPV genotypes on women with normal cytology that come to our hospitalary unit of menopausia. Material and Method: Cross-sectional study; with a random sample of 140 cases of climacteric women of ≥50 years of age, with normal Pap smears for the last 12 months. HPV determination was carried out by PCR for screening, and by hybrid capture for genotype typification. Results: The percentage of climacteric women who are carriers of oncogenic HPV and a normal Pap smear was of 11.43% (16/140 cases). The genotype found most frequently was HPV-16, followed by HPV-58, 51 and 18. Conclusions: We found a high prevalence of women who were carriers of oncogenic HPV in climacteric women with normal Pap smears (latent infections) in our health region. We consider that cervical cancer screening, either by PCR or conventional Pap smear, should not be minimized or ignored from 50 years of age onwards.

Cite this paper

Herrera, M. , Navarrete, I. , López, R. , Rodríguez, S. , Reina, M. and Jiménez, M. (2014) Prevalence and Genotype Distribution of Oncogenic-Risk Human Papilloma Virus in the Cervix of Climacteric Women with Normal Pap Smears. Open Journal of Epidemiology, 4, 164-168. doi: 10.4236/ojepi.2014.43022.

References

[1] De Sanjosé, S., Diaz, M., Catellsague, X., Clifford, G., Bruni, L., Munoz, N. and Bosch, F.X. (2007) Worldwide Prevalence and Genotype Distributión of Cervical Human Papillomavirus DNA in Women with Normal Cytology: A Meta-Analysis. The Lancet Infectious Diseases, 7, 453-459.
http://dx.doi.org/10.1016/S1473-3099(07)70158-5
[2] Dunne, E.F., Unger, E.R., Sternberg, M., McQuillan, G., Swan, D.C., Patel, S.S., et al. (2007) Prevalence of HPV Infecctión among Femalesin the United States. JAMA, 297, 813-819.
http://dx.doi.org/10.1001/jama.297.8.813
[3] Parkin, D.M. (2006) The Global Health Burden of Infection-Associated Cancers in the Year 2002. International Journal of Cancer, 118, 3030-3044.
http://dx.doi.org/10.1002/ijc.21731
[4] Bosch, F.X., Lorincz, A., Munoz, N., Meijer, C.J. and Shah, K.V. (2002) The Causal Relation between Human Papillomavirus and Cervical Cancer. Journal of Clinical Pathology, 55, 244-265.
http://dx.doi.org/10.1136/jcp.55.4.244
[5] Munoz, N., Castellsagué, X., Bernington, A. and Gissmann, L. (2006) HPV in the Etiology of Human Cáncer. Vaccine, 24, S 3/1-10.
[6] Chesson, H.W., Blandford, J.M., Gift, T.L., Tao, G. and Irwin, K.L. (2004) The Estimated Direct Medical Cost of Sexually Trasmitted Disease among American Youth, 2000. Perspectives on Sexual and Reproductive Health, 36, 11-19. http://dx.doi.org/10.1363/3601104
[7] Winer, R.L., Kiviat, N.B., Lee, S.K. and Hughes, J.P. (2005) Development and Duration of Human Papillomavirus Lesion, after Initial Infection. The Journal of Infectious Diseases, 191, 731-738.
http://dx.doi.org/10.1086/427557
[8] Franceschi, S., Herrero, R., Clifford, G.M., Rana, R.K. and Gallus, S. (2006) Variations in the Age-Specific Curves of Human Papillomavirus Prevalence in Women Worldwide. International Journal of Cancer, 119, 2677-2684.
[9] WHO-ICO: HPV Information Centre. Sumary Reports. Update Year 2007.
http://www.hpvcentre.net/summaryreport.php
[10] Mo, L.Z., Monnier-Benoit, S. and Kantelip, B. (2007) Comparison of Amplicor and Hybrid Capture II. Genotyping Assay to Screen the Discordant Results. Journal of Clinical Virology, Nov.22.
[11] Liu, J., Rose, B., Huang, X., Wang, C.J., Yen, C.F. and Lai, C.H. (2004) Comparative Analysis of Characteristics of Women with Cervical Cancer in High-Versis Low-Incidence Regions. Gynecologic Oncology, 94, 803-810.
http://dx.doi.org/10.1016/j.ygyno.2004.06.005
[12] Coupé, V.M.H., Berichof, J., Bullkmans, N.W.J., Snijders, P.I.F. and Maljer, C.J.L.M. (2008) Age-Dependent Prevalence of 14 H. Risk HPV Types in the Netherlands. British Journal of Cancer, 98, 646-651.
http://dx.doi.org/10.1038/sj.bjc.6604162
[13] Kumala, S.M.A., Shabalova, I.P., Petrovitchen, N., Syrjanem, K., Gyllensten, V.B., Syrjanem, S.M. and the NIS Study Group (2007) Prevalence of the Most Commón High-Risk HPV Genotipes among Women in Three New Independent States of the Former Soviet Unión. Journal of Medical Virology, 79, 771-781.
http://dx.doi.org/10.1002/jmv.20839
[14] Munoz, N., Bosch, F.X., De Sanjosé, S., Herrero, R., Castellsague, X., Shah, K.V., et al. (2003) Epidemiologic Classification of Human Papillomavirus Types Associated with Cervical Cancer. The New England Journal of Medicine, 348, 518-527.
http://dx.doi.org/10.1056/NEJMoa021641
[15] Bosch, F.X., Castellsagué, X., Cortés, J., Ptoré, L.M., Roura, E., De Sanjosé, S. and De Torné, A. (2009) Estudio Afrodita: Analisis de la conducta sexual, conocimiento causal del cancer de cervix y su prevención entre las mujeres espanolas. Edición G.S.K., Madrid, 37-53.
[16] Fusté and Brull, P. (2008) Historia natural y oncogénesis del VPH. In: Oncológica, G., Ed., Ergón., Barcelona, 14.

  
comments powered by Disqus

Copyright © 2014 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.